EyeGene Inc. (KOSDAQ:185490)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,455.00
+14.00 (0.97%)
At close: Apr 28, 2026
-55.16%
Market Cap 62.64B
Revenue (ttm) 3.57B
Net Income (ttm) -15.71B
Shares Out 43.23M
EPS (ttm) -562.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 167,445
Average Volume 769,807
Open 1,443.00
Previous Close 1,441.00
Day's Range 1,427.00 - 1,467.00
52-Week Range 1,182.00 - 3,905.00
Beta 0.83
RSI 48.63
Earnings Date May 14, 2026

About EyeGene

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 185490
Full Company Profile

Financial Performance

In 2025, EyeGene's revenue was 3.57 billion, an increase of 6.29% compared to the previous year's 3.36 billion. Losses were -15.71 billion, 29.5% more than in 2024.

Financial Statements

News

There is no news available yet.